Surrey Heartlands

Joint Formulary & PAD

Vibegron - Overactive bladder (adults)

You are here : Home > Formulary Search > Vibegron - Overactive bladder (adults)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NICE
Restrictions / Comments :
Important
Mirabegron is the preferred option where an antimuscarinic is not suitable. Vibegron should have a very limited place in therapy.

Documentation

Guidelines (Local)
Selection tool for OAB treatments - Nov 2024

PAD Profile

ChemicalSubstance :
Vibegron
Indication :
Overactive bladder (adults)
Group Name :
Keywords :
Over-active bladder, OAB, urinary frequency, urge incontinence, LUTS, lower urinary tract symptoms, urinary incontinence, urinary urgency
Brand Names Include :
Obgemsa
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Overactive bladder (adults)
Supporting Documents :
1

Other Indications

Below are listed other indications that Vibegron is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Overactive bladder (adults).

Committee Recommendations (1)

06 Nov 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves vibegron as an option for treating the symptoms of overactive bladder (OAB) syndrome in adults.

Vibegron is only recommended if antimuscarinic medicines are not suitable, do not work well enough or have unacceptable side effects, as recommended by NICE in TA999.

Vibegron for this indication will be considered as GREEN on the traffic light system. Vibegron will be placed alongside mirabegron in the OAB pathway but mirabegron will be the preferred 1st line where both these two treatments may be suitable.

Vibegron does not have an identified place in therapy in preference to mirabegron.

 It was noted that vibegron has a BLACK triangle status with no evidence of advantages over Mirabegron, a well-established treatment, and it is therefore expected to have a very limited place in therapy in Surrey Heartlands ICB until more evidence becomes available